BioCentury
ARTICLE | Clinical News

Onxeo's Livatag misses in Phase III for HCC

October 13, 2017 7:47 PM UTC

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) reported top-line data from the Phase III ReLive trial in 397 patients with unresectable hepatocellular carcinoma (HCC) showing that 20 and 30 mg/m2 doses of IV Livatag doxorubicin (BA-003) every 4 weeks both missed the primary endpoint of improving overall survival (OS) vs. best standard of care (SOC). The company said survival was unexpectedly high in the control arm. The open-label, international trial enrolled patients intolerant to Nexavar sorafenib or who progressed after a systemic therapy including Nexavar. The trial's secondary endpoint evaluated safety. Data were presented at the International Liver Cancer Association meeting in Seoul...

BCIQ Company Profiles

Onxeo S.A.